Back to Home
HealthcareProduct ManagementAIUX Research

MyTrials. Making clinical trials accessible to every patient, everywhere.

A clinician on our team kept watching his patients miss out on treatments that could change their lives — not because the treatments didn't exist, but because the system to find them was built for researchers, not people.

My RoleCo-Founder & UX Designer
IndustryHealthcare
StageCompleted — 2023
Team Size5 people

$200k

Raised

Seed investment secured

5

Team Size

Cross-functional founders

5th

Grade Level

Target reading complexity

97%

Gap

Eligible patients who never enroll

01 — The Origin

A doctor watched his patients miss life-changing treatments

One of our co-founders was a clinician who repeatedly saw the same situation unfold: a patient with a diagnosis that qualified them for a cutting-edge clinical trial — and no idea it existed. The trials were real. The hope was real. The pathway to find them was not.

He brought the problem to our team. We immediately understood the stakes. Clinical trials aren't just research. For many patients, they represent their best option — sometimes their only option — for treatment.

Why clinical trials matter to patients

Free cutting-edge treatment
85%
Closer medical monitoring
78%
Access before public approval
65%
Contributing to medical science
72%

* patients who cited each benefit as a primary motivator

02 — The Problem

The data exists. The interface does not.

We discovered ClinicalTrials.gov — the US government's authoritative database containing over 400,000 active trials. The inventory exists. The problem is the interface.

Eligibility criteria reads like legal-medical hybrid text. Terms like "ECOG performance status ≤2" or "histologically confirmed NSCLC" create an impenetrable wall between patients and the treatments designed to help them. The system was built by researchers for researchers — never for patients.

97%

of eligible cancer patients
never enroll in a clinical trial

Not from reluctance. From a broken system.

03 — The Solution

AI-powered simplification, tested to a 5th-grade reading level

We used GPT-4 to translate clinical trial eligibility criteria into plain English automatically. But we didn't stop there — we ran four rigorous rounds of user testing with non-medical participants, measuring reading level via Flesch-Kincaid scoring until we hit our target without losing essential meaning.

Flesch-Kincaid Grade Level — User Testing Rounds

Round 1
Grade 11 — Too Complex
Round 2
Grade 8 — Still Dense
Round 3
Grade 6 — Borderline
Round 4
Grade 5 — Target Hit ✓

04 — Process

From clinical insight to funded product

01

Clinician Brief

A doctor on our team surfaced the problem: his patients were missing life-changing trials simply because they didn't know they existed.

02

Problem Validation

We mapped the clinical trial enrollment funnel. Only 3% of eligible cancer patients ever enroll — not from reluctance, but from a system that was never designed for patients.

03

Source Discovery

We identified ClinicalTrials.gov as the authoritative database with 400,000+ active trials. The data was there. The usability was not.

04

AI Simplification

We layered GPT-4 on top of the raw trial data to translate dense medical eligibility criteria into plain English that anyone could understand.

05

Readability Testing

We ran 4 rounds of user testing with patients and non-medical professionals, targeting a 5th-grade Flesch-Kincaid reading level while preserving all essential meaning.

06

Brand & Naming

I named the product 'MyTrials' — personal, possessive, and instantly clear. Matching algorithm built. Site launched. $200k raised.

05 — Skills Applied

Product management across a high-stakes domain

Stakeholder Management92%
User Research & Testing88%
Product Strategy85%
Health Literacy Design80%
Investor Storytelling78%
Cross-functional Leadership90%

06 — Tech Stack

Tools that built MyTrials

Framework

Next.js

Framework

React

AI

OpenAI GPT-4

Data

ClinicalTrials.gov API

Database

PostgreSQL

Algorithm

Custom Matching Algo

Design

Figma

Language

TypeScript

07 — Investment

$200,000 raised on the strength of the mission

The investment thesis was clear: the problem is enormous and well-documented, the technology exists, and for the first time the user experience has been built for patients rather than researchers. Investors believed in both the social impact and the commercial opportunity.

$200k

Seed Round

Pre-product investment

5

Team

Clinical + tech + design

400k+

Data Source

Active ClinicalTrials.gov entries